General Statement of the International Society for the Study of Women's Sexual Health

The International Society for the Study of Women's Sexual Health (ISSWSH), the preeminent scientific organization focused on research, education, and clinical practice of women's sexuality, applauds the FDA's recent announcement of it's upcoming Joint Meeting of the Bone, Reproductive and Urologic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee on June 4, 2015.

The meeting culminates the prolonged development of flibanserin, a drug that could be the first approved medical treatment for distressing low sexual desire. Flibanserin offers a favorable safety and efficacy profile for the treatment of Hypoactive Sexual Desire Disorder in women. While we fully endorse the FDA's evidence-based review of the risks and benefits of this treatment, ISSWSH wishes to emphasize the significant unmet need for safe and effective medical therapies to address all women's sexual problems.

Save the Date

ISSWSH Sexual Pain Course 2020
April 17-18, 2020
CANCELLED DUE TO COVID-19
Read more...

ISSWSH Fall Course 2020
November 19-21, 2020   177 days left
DoubleTree Hilton Hotel, Scottsdale, AZ - USA
Read more...

ISSWSH Annual Meeting 2021
March 4-7, 2021   282 days left
Renaissance Dallas Hotel, Dallas, TX, USA

Latest Tweets

In observance of Memorial Day, our office will be closed today. Stay well everyone! ISSWSH
Retweet if you plan on tuning in for our webinar this Wednesday, May 27! We can't wait to see you there.… https://t.co/43FnQunHnr ISSWSH
Botox - it's not just for wrinkles anymore. New review article looks at different ways it can alleviate sexual pain… https://t.co/nvgWFGWSR4 ISSWSH

Contact Details

ISSWSH Executive Office
14305 Southcross Dr
Suite 100
Burnsville, MN 55306
USA

Phone: +1 (952) 683 9025
Fax: +1 (952) 314 8212
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

Follow Us

On Twitter
On Facebook
On Instagram